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doi:10.1016/j.jds.2010.11.005Abstract Background/purpose: Periodontal disease is a plaque-induced infection; therefore
successful periodontal therapy is dependent on anti-infective procedures. Currently, many
clinicians use a combination of adjunctive chemotherapeutic agents in non-surgical
periodontal therapy. The purpose of this study was to evaluate the clinical efficacy of using
triclosan/copolymer toothpaste on improving the periodontal health during phase I periodontal
treatment.
Materials and methods: This study was performed at the Department of Periodontics, Chung
Shan Medical University Hospital. Forty participants with generalized chronic periodontitis
who provided informed consent were included in the study. At the baseline examination,
the pocket depth (PD), clinical attachment loss (CAL), bleeding on probing (BOP), and full-
mouth plaque score (FMPS) were recorded before phase I therapy began. The subjects were
assigned to 2 groups. The experimental group used a triclosan/copolymer-containing tooth-
paste, whereas the control group used only a standard fluoride toothpaste without antibacte-
rial ingredients. All participants received full-mouth ultrasonic scaling and root planing with
intensive oral hygiene instruction. After 6 weeks, the examinations were repeated and results
recorded.
Results: There were no statistical significant differences (P> 0.05) in the baseline data
collected between the experimental and control groups. After phase I therapy, the PD, CAL,
BOP, and FMPS all improved in both the control and experimental groups (P< 0.05). The use
of triclosan/copolymer toothpaste was found to have significantly reduced the BOP and FMPS
compared to the control group (P< 0.05). In the group with PDs >6 mm, the PD and CAL also
showed significant improvements versus the control group (P< 0.05).hool of Dentistry, Chung Shan Medical University, No.110, Chien-Kuo N. Road, Sec. 1, Taichung 40201,
; fax: þ886 4 24759065.
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Effects of a triclosan/copolymer dentifrice 217Conclusion: An oral hygiene regimen including triclosan/copolymer-containing toothpaste can
sustain the short-termeffectofphase I therapy for patientswith generalized chronic periodontitis.
Copyright ª 2010, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Figure 1 Distribution of participants in this study. OHI, o.;
PD, pocket depth; CAL, clinical attachment loss; BOP, bleeding
on probing; FMPS, full-mouth plaque score.Introduction
Periodontitis is a common inflammatory disease affecting
the tissues that comprise the dental support structures: the
gingiva, cementum, periodontal ligament, and alveolar
bone. An oral microbial biofilm is the major factor in the
pathogenesis of the disease.1 When a host is overwhelmed,
the pathogenic supragingival bacteria migrate subgingivally
and form a subgingival biofilm that can be highly detri-
mental to the surrounding periodontal structures.2
Successful periodontal therapy is dependent on anti-
infective procedures aimed at eliminating the pathogenic
organisms found in dental plaque associated with the tooth
surface.3e5 Anti-infective therapy includes both mechanical
and chemotherapeutic approaches. Mechanical therapy
consists of both supragingival and subgingival scalings as well
as root planing via the meticulous use of hand or power-
driven scalers to remove plaque, endotoxin, calculus, and
other local plaque-retentive factors.6 Chemotherapeutic
approaches, including application of topical antiseptics,7e9
such as chlorhexidine, triclosan, hydrogen peroxide, baking
soda, and povidone iodine, can be applied professionally as
an adjunct to mechanical debridement.8,9
Chemical agents were shown to support periodontal
therapy.10,11 Among different chemical products, the use of
toothpaste can easily be handled and acquired. The
bisphenolic, non-cationic, lipid-soluble compound, triclosan
(2,4,40-trichloro-2 hydroxydiphenylether), has potent anti-
bacterial as well as anti-inflammatory properties. Previous
studies demonstrated that Colgate Total (Colgate-Palmo-
live, Piscataway, NJ, USA), containing 0.3% triclosan, 2.0%
copolymer, and fluoride (1100⁄1450 ppm), maintains
concentrations of triclosan in the plaque that exceeds the
minimum inhibitory concentration values of many plaque
bacteria for up to 12 h.12 In addition, the daily use of a tri-
closan/copolymer-containing dentifrice was found to
reduce signs of gingivitis, and may also retard the progres-
sion of chronic periodontitis in susceptible subjects.13,14
The aim of this study was to evaluate the clinical effi-
cacy of the daily use of a triclosan/copolymer-containing
toothpaste and determine if it can enhance clinical
outcomes during phase I therapy for patients with gener-
alized chronic periodontitis.
Materials and methods
Patient selection
This study was performed in the Department of Periodon-
tics, Chung Shan Medical University Hospital. In total, 40
adult patients (21 males and 19 females) with generalized
chronic periodontitis15 were recruited after informed
consent was obtained. The inclusion and exclusion criteria
are described here.Inclusion criteria included no use of any triclosan-con-
taining products over the past month, such as a mouth rinse,
toothpaste, or chewing gum; more than 20 teeth remaining
in the mouth; and more than 30% of the teeth with >5 mm
of clinical attachment loss (CAL); and this was the first time
to receive comprehensive periodontal treatment.
Exclusion criteria included having taken an antibiotic
drug in the past 3 months; needing prophylaxis during the
periodontal treatment; use of any other antiseptic prod-
ucts or chlorhexidine-containing mouth rinse; being preg-
nant; and suffering from another chronic medical disease/
condition.
Experimental procedures
The experimental procedure is illustrated in Fig. 1. The
participants received information about periodontal treat-
ment and instructions for performing efficient oral hygiene.
A baseline examination was performed recording pocket
depth (PD), CAL, bleeding on probing (BOP)16, and a full-
mouth plaque score (FMPS).17 A periodontal probe (Gold-
man-Fox/Williams Probe, Hu-Friedys, Chicago, IL, USA) was
used to measure the PD and CAL to the nearest millimeter
at the mesiobuccal, mid-buccal, distobuccal, mesiolingual,
mid-lingual, and distolingual sides of each tooth. All
assessments were performed by a single experienced
periodontist.
Following the initial examination, all 40 subjects were
assigned to 2 groups. Thirty subjects in the experimental
group were given a dentifrice containing 0.3% triclosan, 2%
copolymer, and 0.243% sodium fluoride (Colgate Total),
while the other 10 participants in the control group were
supplied with a fluoride-containing dentifrice (Hawley &
Hazel Chemical Company, Taipei, Taiwan). Participants
Table 2 Clinical measurements in the experimental and
control groups at the baseline and the 6-wk reevaluation.
Baseline Reevaluation
Pocket depth (mm)
Triclosan/copolymer 3.68 0.83 2.97 0.55*
Control 3.66 0.58 2.92 0.56*
Clinical attachment loss (mm)
Triclosan/copolymer 4.93 1.07 4.36 1.10*
Control 4.94 0.89 4.31 1.03*
Bleeding on probing (%)
Triclosan/copolymer 68.1 25.06 31.37 19.43*
Control 58.2 24.45 41 22.4*
Full-mouth plaque score (%)
Triclosan/copolymer 70.4 18.79 38.08 18.69*
Control 61.7 11.40 48.1 13.54*
* Statistically significantly differed from the baseline (P< 0.05).
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in the morning and before sleep, for 3 min each time with
the toothpaste provided. Subjects were not allowed to use
any other dentifrice or mouth rinse, and to enhance
compliance, an oversupply of products was provided.
Patients received phase I treatment, including thorough
supra- and sub-gingival dental plaque and calculus
debridement. The treatment was performed and completed
by an experienced periodontist, and then participants were
evaluated, and baseline measurements were recorded. All
measurements were repeated every 2 weeks with a final
evaluation at 6 weeks post-treatment.
A further analysis was performed for the PD and CAL
according to the initial PDs and sites were divided into 3
categories: (i) shallow pockets with PDs of <4 mm, (ii)
moderate pockets with 4 mm PD 6 mm, and (iii) deep
pockets with PDs of >6 mm.
Statistical analysis
The intra-examiner variability test demonstrated that the
reproducibility of the measurements of PD and CAL within
1 mm was 96%. Differences over time within groups for
the clinical results were analyzed by the non-parametric
Wilcoxon’s signed-ranks test. Comparisons between the
control and test groups were performed with the Wilcoxon
rank-sum test. The level of significance was set to P< 0.05.
All statistical analyses were carried out with the aid of
statistical software (SPSS vers. 12.0, Chicago, IL, USA).
Results
As shown in Table 1, there were no remarkable differences
in demographic parameters between the experimental and
control groups (P> 0.05). No remarkable differences in the
periodontal status were noted between the experimental
and control groups at the baseline (P> 0.05).
After phase I therapy, the PD, CAL, BOP, and FMPS were
found to have improved in both the control and experi-
mental groups (P< 0.05) (Table 2). The use of the triclo-
san/copolymer toothpaste was found to have significantly
reduced the BOP and FMPS compared to the control group
(P< 0.05) (Table 3). However, there were no statisticalTable 1 Patient demographics including age, gender, the
initial pocket depth (PD), clinical attachment loss (CAL),
bleeding on probing (BOP), and full-mouth plaque score
(FMPS).
Triclosan/copolymer Control
N 30 10
Age (years) 53.23 11.9 60 15.75
Gender (male/female) 50%/50% 60%/40%
Initial PD (mm) 3.68 0.83 3.66 0.58
Initial CAL (mm) 4.93 1.07 4.94 0.89
Initial BOP (%) 68.1 25.06 58.2 24.45
Initial FMPS (%) 70.4 18.79 61.7 11.40
There were no significant differences in demographics between
the experimental and control groups (P> 0.05).significances between the 2 groups in the PD and CAL post-
treatment measurements (P> 0.05).
The PD and CAL measurements were further analyzed for
the 3 different categories of initial PD. As shown in Fig. 2, the
use of triclosan/copolymer toothpaste was found to have
significantly reduced the PD in the deep-pocket subgroup
(PD> 6 mm) compared to the control group (P< 0.05).
However, there were no significant differences in pocket
reduction among the shallow-pocket subgroup (PD< 4 mm),
moderate-pocket subgroup (4 mm PD 6 mm), or control
group (P> 0.05).
A similar pattern was found for CAL measurements. Only
in the deep pocket subgroup, the CAL showed a significant
reduction compared with the control group (P< 0.05)
(Fig. 3).
Discussion
Chronic periodontitis is the most common oral disease
found in adults and the leading cause of loss of dentition.18
It is associated with the accumulation of plaque and
calculus and generally has a slow to moderate rate of
disease progression, but periods of more-rapid destruction
may be observed.19 The disease can also be described by its
severity as slight, moderate, or severe based on the amount
of CAL. Phase I therapy without surgery might not be
effective for deep pockets.20 Therefore, chemotherapeutic
agents, such as triclosan/copolymer, with its antimicrobial
and anti-inflammatory effects may be used as an adjunctive
agent to control moderate or severe chronic periodontitis.
The focus of any attempt to prevent and control peri-
odontal disease is the maintenance of an effective level of
plaque control. In this study, subjects using the triclosan/
copolymer dentifrice showed a significantly reduced level
of dental plaque compared to those of the control group.
Similar results were found in previous long-term studies
demonstrating the efficacy of the use of triclosan/copol-
ymer dentifrices in inhibiting plaque formation.21e23 It was
shown that the range of percentage plaque reductions for
a triclosan/copolymer toothpaste versus a fluoride control
was 0e59%. Those studies suggested that the use of
Table 3 Clinical efficacy at the 6-week reevaluation.
Triclosan/copolymer Control
Reduction in the pocket depth (mm) 0.70 0.52 0.74 0.36
Gain in the clinical attachment loss (mm) 0.56 0.6 0.63 0.46
Reduction in bleeding on probing (%) 36.73 22.73 * 17.2 8.9
Reduction in the full-mouth plaque score (%) 32.32 22.85 * 13.6 13.33
* Statistically significantly different between the experimental and control groups (P< 0.05) [Participants (nZ 40, 21 males and 19
females)/OHI, baseline measurements (PD, CAL, BOP, and FMPS)/Experimental group (nZ 30, 15 males and 15 females)/Control group
(nZ 10, 6 males and 4 females)/1e2 weeks/4e6 weeks/8 weeks/Every 2 weeks, participants were reevaluated].
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performed oral hygiene procedures may have a profound
effect on dental plaque formation in the general population
as well as in populations with chronic periodontitis.
BOP is easily detected clinically and is the best clinical
indicator of gingival inflammation.24 In 1 meta-analysis,25 it
was demonstrated that the gingival bleeding condition of
the population using the triclosan/copolymer-containing
dentifrice had decreased 49% compared to those using
a standard fluoride toothpaste. Another short-term double-
blinded randomized clinical trial26 reported that volunteers
with gingivitis had a 30% decrease in the BOP in the tri-
closan/copolymer-containing dentifrice group. Our results
are in agreement with those previous studies. Triclosan is
well documented to be a significant inhibitor of inflamma-
tory mediators, such as tumor necrosis factor-a, inter-
leukin-1b, and prostaglandin E2.
27,28 It is likely that both
antibacterial and anti-inflammatory properties of triclosan
may play a similar role in the sustained gingival health
observed in the present trial.Figure 2 Data demonstrating the reduction in pocket depths
(PDs) at the 6-week reevaluation. In the analysis of the initial
PD< 4 mm and 4 mm PD 6 mm, there was no significant
main effect of the dentifrice. However, the use of triclosan/
copolymer toothpaste was found to have significantly reduced
the PD in subjects the PDs of which were >6 mm, compared to
the control group. * Indicates a statistically significant differ-
ence from the baseline (P< 0.05). # Indicates a statistically
significant difference between the control group and the test
group (P< 0.05).Periodontal parameters, i.e., the PD and CAL, signifi-
cantly improved following phase I therapy in both the
experimental and control groups in the present study.
There were no significant differences in the reduction in PD
or the gain in CAL between the 2 groups. However, in
a long-term study following non-surgical therapy,29 the use
of a triclosan product exhibited a significantly greater
reduction in the PD and improvement in CAL compared to
those using the fluoride-containing dentifrice. The reason
for this contradictory result is not clear. It may have been
a result of (i) different specific subjects, (ii) a shorter
follow-up period, or (iii) evaluation of the oral hygiene
status and use of toothpaste every 2 weeks.
Pockets of varying depth may respond differently to
phase I therapy. Therefore, sites are usually analyzed in 3
categories of initial probing depths: 1e3, 4e6, and >6 mm.
This approach of presenting results based on these 3 cate-
gories was used by most studies including the present
systematic review. In the analysis of the initial PD of
4 mm, there was no significant additional effect of the
dentifrice. However, there was a significant interactionFigure 3 Data demonstrating the reduction in clinical
attachment loss at the reevaluation. In the analysis of the
initial pocket depth (PD)< 4 mm and 4 mm PD 6 mm, there
was no significant main effect of the dentifrice. However, the
use of triclosan/copolymer toothpaste was found to have
significantly reduced the PD in subjects, the pocket depths of
which were >6 mm, compared to the control group. * Indicates
a statistically significant difference from the baseline
(P< 0.05). # Indicates a statistically significant difference
between the control group and the test group (P< 0.05).
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The use of triclosan/copolymer toothpaste was found to
significantly reduce PDs in the deep-pocket subgroup
(PD> 6 mm) compared to the control group. It is difficult to
thoroughly debride deep-pocket sites in phase I therapy for
additional improvements without the use of chemothera-
peutic agents.
In conclusion, the findings of the present study indicate
that an oral hygiene regimen including the use of a triclo-
san/copolymer dentifrice may sustain the adjunct effects
of phase I therapy in subjects with chronic periodontitis.
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